TY - CHAP M1 - Book, Section TI - HEPARINS A1 - Villano, Janna H. A2 - Olson, Kent R. A2 - Anderson, Ilene B. A2 - Benowitz, Neal L. A2 - Blanc, Paul D. A2 - Clark, Richard F. A2 - Kearney, Thomas E. A2 - Kim-Katz, Susan Y. A2 - Wu, Alan H. B. Y1 - 2018 N1 - T2 - Poisoning & Drug Overdose, 7e AB - Heparins (Table II–32) have been used for many years as injectable anticoagulants for prophylaxis of thromboembolic disease and management of multiple conditions including hypercoagulable disorders, venous thromboembolic disease, acute coronary syndrome, and to maintain patency in intravascular access and hemodialysis machines. Conventional or unfractionated heparin (UFH) is primarily administered in health care settings and thus intentional overdoses are rare; most cases involve inadvertent iatrogenic administration errors. Low–molecular-weight-heparins (LMWHs) are obtained from UFH and have greater bioavailability, longer half-life, predictable anticoagulation with a fixed-dose schedule, and are more easily self-administered by patients in outpatient settings. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=1174606034 ER -